1. Pirmohamed M, James S, Meakin S et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15–8.
2. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs. N Engl J Med 1999; 340: 1888–91.
3. Каратеев А.Е., Насонова В.А. Развитие и рецидивирование язв желудка и двенадцатиперстной кишки у больных, принимающих НПВП: влияние стандартных факторов риска. Тер архив. 2008; 5: 62–6.
4. Singh G, Ramey DR, Morfeld D et al. Gastrointestinal tract complications of nonsteroidal antiinflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996; 156: 1530–6.
5. Smalley WE, Griffin MR. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am 1996; 25: 373–96.
6. Süleyman H, Demircan B, Karagöz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol Rep 2007; 59 (3): 247–58.
7. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Nat Acad Sci USA 1992; 89: 7384–88.
8. Seibert K, Zhang Y, Leahy K et al. Distribution of COX-1 and COX-2 in normal and inflamed tissues. Adv Exp Med Biol 1997; 400A: 167–70.
9. Seibart K, Zhang Y, Leahy K et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain. Proc Nat Acad Sci USA 1994; 91: 12013–17.
10. Mitchell JA, Warner TD. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 1999; 128: 1121–32.
11. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular and molecular biology. Ann Rev Biochem 2000; 69: 145–82.
12. Radford MG, Holley KE, Grande JP et al. Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs. JAMA 1996; 276: 466–8.
13. Насонова В.А. Клиническая оценка нестероидных противовоспалительных препаратов в конце ХХ века. РМЖ. 2000; 8 (17): 714–7.
14. Zeidler H, Kaltwasser J, Leonard J et al. Prescription and tolerability of meloxicam in day-to-day practice. Postmarketing observational cohort study of 13.307 patients in Germany. J Clin Rheumatol 2002; 8: 305–15.
15. Mengle-Gaw LJ, Schwartz BD. Cyclooxygenase-2 inhibitors: promise or peril? Mediators Inflamm 2002; 11: 275–86.
16. Armstrong CP, Blower AL. Nonsteroidal antiinflammatory drugs and life-threatening complications of peptic ulceration. Gut 1987; 28: 527–32.
17. Silverstein FE, Graham DY, Senior JR et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241–9.
18. Rahme E, Joseph L, Kong SX et al. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum 2000; 43: 917–24.
19. Bresalier R, Sandler R, Quan H et al. Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial. N Engl J Med 2005; 352: 1092–102.
20. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433–42.
21. Merck announces voluntary worldwide withdrawal of VIOXX. http://www.vioxx.com/vioxx/documents/english/hcp_notification_physicians.pdf.
22. Михайлов И.Б. Настольная книга врача по клинической фармакологии. Руководство для врачей. СПб: Фолиант, 2001.
23. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289–300.
24. Aw T-J, Haas S, Liew D. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165: 490–96.
25. Strom BL, Carson JL, Schinnar R et al. Nonsteroidal anti-inflammatory drugs and neutropenia. Arch Intern Med 1993; 153: 2119–22.
26. Patton W, Duffull S. Idiosyncratic drug-induced hematological abnormalities. Drug Safety 1994; 11 (6): 445–62.
27. Зборовский А.Б., Тюренков И.Н. Осложнения фармакотерапии. М.: Медицина, 2003.
28. Harrington LS, Lucas R, McMaster SK et al. COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma. FASEB J 2008; 22 (11): 4005–10.
29. Teoh NC, Farrell GC. Hepatotoxicity associated with non-steroidal anti-inflammatory drugs. Clin Liver Dis 2003; 7: 401–13.
30. Bort R, Ponsoda X, Jover R et al. Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity. J Pharmacol Exp Ther 1999; 288 (1): 65–72.
31. Pathan E, Gaitonde S, Rajadhyaksha S et al. A longitudinal study of serum creatinine levels in patients of rheumatoid arthritis on long term NSAID therapy. J Assoc Physicians India 2003; 51: 1045–9.
32. Galesic K, Morovic-Vergles J. Drug-induced acute interstitial nephritis. Reumatizam 2003; 50 (1): 14–7.
33. Joannidis M. Drug-induced renal failure in the ICU. Int J Artif Organs 2004; 27 (12): 1034–42.
34. Rainsford KD. Relationship of nimesulide safety to its pharmacokinetics: assessment of adverse reactions. Rheumatology (Oxford). 1999; 38 (Suppl. 1): 4–10.
35. Rainsford KD. Nimesulide – a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin 2006; 22 (6): 1161–70.
36. Котова О.В. Боль в спине: предотвратить хронизацию. РМЖ. Неврология. Психиатрия. 2011; 30: 1872–3.
37. Binning A. Nimesulide in the treatment of postoperative pain: a double-blind, comparative study in patients undergoing arthroscopic knee surgery. Clin J Pain 2007; 23 (7): 565–70.
38. Pohjolainen T, Jekunen A, Autio L et al. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine 2000; 25 (12): 1579-85.
39. Каратеев А.Е., Каратеев Д.Е., Лучихина Е.Л. и др. Эффективность и безопасность монотерапии высокими дозами НПВП при раннем артрите. РМЖ. 2006; 16: 24–9.
40. Bradbury F. How important is the role of the physician in the correct use of a drug? An observational cohort study in general practice. Int J Clin Pract 2004; 144 (Suppl.): 27–32.
41. Marini U, Spotti D, Magni E et al. Double-blind endoscopic study comparing the effect of nimesulide and placebo on gastric mucosa of dyspeptic patients. Drug Invest 1990; 2: 162–6.
42. Davis R, Brogden RN. Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1994; 48: 431–54.
43. Boelsterli U. Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide. Drug Saf 2002; 25: 633–48.
44. Helin-Salmivaara A, Virtanen A, Veslainen R et al. NSAID use and the risk of hospitalisation for first myocardial infarction in the general population: a national case-control study from Finland. Eur Heart 2006; 27: 1657–63.
45. Kriegel W, Korff K, Ehrlich J et al. Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis. Int J Clin Pract 2001; 55 (8): 510–14.

О.В.Котова

ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздравсоцразвития РФ